PTC Therapeutics, Inc.

PTCT

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001070081

D

fourth fifth of 370 graded peers in healthcare

rank 250 of 370; percentile 67.5; sampling error 2.5 points; lower is stronger

A B C D E

D, the sloth



Scoreboard

Profitability	D/E	percentile 78.2
Solvency	C	percentile 50.0
Growth and financing	B	percentile 31.9
Reliability	0.94 AUC	filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year	Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets	total assets $2.9B
Standard universe	inside	revenue above $1M and assets above $10M
Warnings	none triggered	not computable: fortress balance sheet
Inputs computable	8 of 14	
Graded from	filings received through Feb 19, 2026	242 days before the rescan; latest periodic filing 10-Q received Jul 30, 2026
Last close	$59.27	2026-10-16; market equity $4.9B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 19, 2026

Our competitors may develop products that are more effective, safer, more convenient or less costly than any that we are marketing or developing or that would render our products or product candidates obsolete or non-competitive. Our competitors may also obtain marketing authorization for their products more rapidly than we may obtain approval for our products and product candidates, which could result in our competitors establishing a strong market position before we are able to enter the market.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 78.2						
Gross profitability	not computable	32.3%				
latest aligned inputs end 2019-12-31; latest annual assets end 2025-12-31						
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(1.2%)	(6.6%)	78.2	812	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 1					
Solvency, sleeve percentile 50.0					
Twelve-month failure probability	0.08%	0.07%	52.8	247	2026-06-30
Altman Z double-prime	1.56	(0.30)	30.6	757	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	2.35x	2.96x	66.5	840	2025-12-31
Growth and financing, sleeve percentile 31.9					
Revenue growth, three-year compound	35.3%	10.1%	19.1	414	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	57.8%	37.1%	41.7	104	2025-12-31
Asset growth, three years	19.3%	2.1%	21.6	705	2025-12-31
Net share issuance, one year	5.0%	2.5%	45.0	634	2026-02-18

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
245	InspireMD, Inc. (NSPR)	66.1	D	dilution, short runway, distress
246	Angiodynamics Inc. (ANGO)	66.4	D	fortress balance sheet
247	Alpha Teknova, Inc. (TKNO)	66.7	D	
248	AIM ImmunoTech Inc. (AIM)	66.9	D	late filer, degenerate inputs, distress
249	Exagen Inc. (XGN)	67.2	D	dilution, fortress balance sheet
250	PTC Therapeutics, Inc. (PTCT)	67.5	D	
251	Amylyx Pharmaceuticals, Inc. (AMLX)	67.8	D	short runway, degenerate inputs
252	U S Physical Therapy Inc. (USPH)	68.0	D	
253	American Shared Hospital Services (AMS)	68.3	D	late filer
254	Adaptive Biotechnologies Corp. (ADPT)	68.6	D	
255	Orchestra BioMed Holdings, Inc. (OBIO)	68.8	D	dilution, short runway, fortress balance sheet

What the price implies

at the 2026-10-16 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	13.3%	8.0%	53
Distance from 52-week high	(33.8%)	(33.0%)	48
EBIT to enterprise value	21.7%	(1.7%)	98
Free cash flow yield	14.2%	(1.0%)	94

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Book value to price	(0.03)	0.28	9
Sales to price	0.35	0.31	54
Composite equity issuance, five years	17.1%	20.3%	47
Relative strength against the sector, log excess return	(0.09)	(0.13)	53

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$1.0B
Operating cash flow, four quarters	-$30.5M
Months of runway	413.0
Days since last periodic filing	81 (10-Q received Jul 30, 2026)
Median daily dollar volume, 63 sessions	$67.7M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$307.0M	2019-12-31	2020-03-02	10-K	20-000064
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$12.1M	2019-12-31	2020-03-02	10-K	20-000064
3	assets	us-gaap:Assets	$1.6B	2019-12-31	2021-02-25	10-K	21-000009
4	net income	us-gaap:NetIncomeLoss	$682.6M	2025-12-31	2026-02-19	10-K	26-017575
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$711.2M	2025-12-31	2026-02-19	10-K	26-017575
6	assets	us-gaap:Assets	$2.9B	2025-12-31	2026-02-19	10-K	26-017575
7	assets	us-gaap:Assets	$1.7B	2024-12-31	2026-02-19	10-K	26-017575
8	current assets	us-gaap:AssetsCurrent	$2.3B	2025-12-31	2026-02-19	10-K	26-017575
9	current liabilities	us-gaap:LiabilitiesCurrent	$968.4M	2025-12-31	2026-02-19	10-K	26-017575
10	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$3.0B	2025-12-31	2026-02-19	10-K	26-017575
11	operating income	us-gaap:OperatingIncomeLoss	$866.9M	2025-12-31	2026-02-19	10-K	26-017575
12	book equity	us-gaap:StockholdersEquity	-$205.3M	2025-12-31	2026-02-19	10-K	26-017575
13	liabilities	us-gaap:Liabilities	$3.1B	2025-12-31	2026-02-19	10-K	26-017575
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.7B	2025-12-31	2026-02-19	10-K	26-017575
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$806.8M	2024-12-31	2026-02-19	10-K	26-017575
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$937.8M	2023-12-31	2026-02-19	10-K	26-017575
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$698.8M	2022-12-31	2025-02-27	10-K	25-000012
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$8.9M	2025-12-31	2026-02-19	10-K	26-017575
19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$107.7M	2024-12-31	2026-02-19	10-K	26-017575
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$6.5M	2024-12-31	2026-02-19	10-K	26-017575
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$158.4M	2023-12-31	2026-02-19	10-K	26-017575
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$28.4M	2023-12-31	2026-02-19	10-K	26-017575
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$356.7M	2022-12-31	2025-02-27	10-K	25-000012
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$32.0M	2022-12-31	2025-02-27	10-K	25-000012
25	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$38.8M	2025-12-31	2026-02-19	10-K	26-017575
26	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$696.6M	2025-12-31	2026-02-19	10-K	26-017575

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

27	income tax	us-gaap:IncomeTaxExpenseBenefit	$14.0M	2025-12-31	2026-02-19	10-K	26-017575
28	current assets	us-gaap:AssetsCurrent	$1.4B	2024-12-31	2026-02-19	10-K	26-017575
29	current liabilities	us-gaap:LiabilitiesCurrent	$581.0M	2024-12-31	2026-02-19	10-K	26-017575
30	assets	us-gaap:Assets	$1.9B	2023-12-31	2025-02-27	10-K	25-000012
31	assets	us-gaap:Assets	$1.7B	2022-12-31	2024-02-29	10-K	24-002196
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	82,774,730	2026-02-18	2026-02-19	10-K	26-017575
33	shares outstanding	dei:EntityCommonStockSharesOutstanding	78,869,368	2025-02-25	2025-02-27	10-K	25-000012

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.